Comparing the Effects of the Platelet-Rich Plasma Gel with Wound Therapeutic Methods on the Treatment of Diabetic Foot

Document Type : Original Article (s)

Authors

1 Professor, Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 PhD Student, Department of Psychiatry, Student Research Committee, School of Humanities, Rasht Branch, Islamic Azad University, Rasht, Iran

4 Professor, Department of Infectious Diseases and Tropical Medicine, School of Medicine AND Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

5 Associate Professor, Hematopoietic Stem Cell Transplantation Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

6 Resident, Department of Infectious Diseases and Tropical Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The aim of this study was to evaluate the effects of platelet-rich plasma (PRP) gel on the diabetic wound in order to find a new safe and effective treatment method.Methods: In this randomized clinical trial, 50 patients with diabetic wound were selected and randomly allocated into two groups. In the intervention group, 1 ml of platelet-rich plasma was administered topically at the wound edges, 3 times with one-week interval. The control group received routine treatment. Quality of life, pain score, wound extent, and incidence of infection were evaluated for all the patients within the first 3 months.Findings: The mean score of quality of life after the first month in both groups was similar. However, the mean score of quality of life in the control group was lower than the intervention group after 2 and 3 months (31.88 ± 2.8 vs. 39.13 ± 1.35, respectively, P < 0.001 for both). The pain score in platelet-rich plasma group was significantly lower after 1 month as compared to the control group. It difference remained significant after 3 months (2.4 ± 0.59 vs. 3.05 ± 0.7, P = 0.003). The area of the wound was significantly better in platelet-rich plasma group after 2 weeks.Conclusion: Platelet-rich plasma gel seems to be effective in the treatment of diabetic foot. It is likely that this combination can be used as a treatment option in addition to standard treatment to be effective in controlling the wound and infection in short term. Considering the limitations of this study including small sample size, more studies are recommended.

Keywords

References

  1. Lantion-Ang LC. Epidemiology of diabetes mellitus in Western pacific region: Focus on Philippines. Diabetes Res Clin Pract 2000; 50(Suppl 2): S29-S34.
  2. Larejani B, Zahedi F. Epidemiology of diabetes mellitus in Iran. Iran J Diabetes Lipid Disord 2001; 1(1): 1-8. [In Persian].
  3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-53.
  4. Dunstan DW, Zimmet PZ, Welborn TA, De Court MP, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25(5): 829-34.
  5. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, et al. Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994; 11(3): 299-303.
  6. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003; 290(14): 1884-90.
  7. Larijani B, Bastan Hagh M H, Pajouhi M, Afshari M, Khani M, Shagareyan M. Lower limb amputation rate in patients with type 2 diabetes managed at the Imam Khomeiny and Doctor Shariati hospitals between 1979 and 1994. Iran J Diabetes Lipid Disord 2001; 1(1): 83-85. [In Persian].
  8. Larijani B, Afshari M, Darvishzadeh F, Bastanhagh M, Pajouhi M, Baradar Jallili R, et al. Lower limb amputation in patients with diabetic foot ulcer: A 22 year review. Iran Red Crescent Med J 2006; 8(3): 21-4.
  9. Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care 2003; 26(2): 491-4.
  10. Harrington C, Zagari MJ, Corea J, Klitenic J. A cost analysis of diabetic lower-extremity ulcers. Diabetes Care 2000; 23(9): 1333-8.
  11. Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 1999; 14(4): 529-35.
  12. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001; 24(3): 483-8.
  13. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85(6): 638-46.
  14. Man D, Plosker H, Winland-Brown JE. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery. Plast Reconstr Surg 2001; 107(1): 229-37.
  15. Hee HT, Majd ME, Holt RT, Myers L. Do autologous growth factors enhance transforaminal lumbar interbody fusion? Eur Spine J 2003; 12(4): 400-7.
  16. Kakudo N, Minakata T, Mitsui T, Kushida S, Notodihardjo FZ, Kusumoto K. Proliferation-promoting effect of platelet-rich plasma on human adipose-derived stem cells and human dermal fibroblasts. Plast Reconstr Surg 2008; 122(5): 1352-60.
  17. Mohammadi MH, Molavi B, Mohammadi S, Nikbakht M, Mohammadi AM, Mostafaei S, et al. Evaluation of wound healing in diabetic foot ulcer using platelet-rich plasma gel: A single-arm clinical trial. Transfus Apher Sci 2017; 56(2): 160-4.
  18. Ahmed M, Reffat SA, Hassan A, Eskander F. Platelet-rich plasma for the treatment of clean diabetic foot ulcers. Ann Vasc Surg 2017; 38: 206-11.
  19. Picard F, Hersant B, Bosc R, Meningaud JP. The growing evidence for the use of platelet-rich plasma on diabetic chronic wounds: A review and a proposal for a new standard care. Wound Repair Regen 2015; 23(5): 638-43.
  20. Dougherty EJ. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers. Adv Skin Wound Care 2008; 21(12): 568-75.
  21. Martinez-Zapata MJ, Marti-Carvajal AJ, Sola I, Exposito JA, Bolibar I, Rodriguez L, et al. Autologous platelet-rich plasma for treating chronic wounds. Cochrane Database Syst Rev 2016; (5): CD006899.
  22. Argolo Neto NM, Del Carlo RJ, Monteiro BS, Nardi NB, Chagastelles PC, de Brito AF, et al. Role of autologous mesenchymal stem cells associated with platelet-rich plasma on healing of cutaneous wounds in diabetic mice. Clin Exp Dermatol 2012; 37(5): 544-53.
Journal of Isfahan Medical School
Volume 35, Issue 450 - Serial Number 450
September and October 2017
Pages 1389-1395

Files

History

  • Receive Date: 10 September 2017
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics